<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122404</url>
  </required_header>
  <id_info>
    <org_study_id>OP_861</org_study_id>
    <nct_id>NCT04122404</nct_id>
  </id_info>
  <brief_title>POC Strategies to Improve TB Care in Advanced HIV Disease</brief_title>
  <acronym>TBPOC</acronym>
  <official_title>Point-of-care Strategies to Improve Tuberculosis Care Among Severely Immunosuppressed HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Tuberculosis Control Programme, Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense Patient Data Explorative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tema General Hospital, Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lekma Hospital, Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korle-Bu Teaching Hospital, Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis (TB) remains the major cause of morbidity and mortality among patients with HIV.
      Sub-optimal diagnostics contributes towards poor patient outcome and there is an urgent need
      to identify non-sputum-based point-of-care diagnostic tests. The urine based lateral flow
      lipoarabinomannan TB diagnostic test (LF-LAM) is a simple, inexpensive point-of-care test. In
      2015, the World Health Organization endorsed LF-LAM for conditional use among patients with
      advanced HIV, but uptake of the test in clinical practices has been poor.

      The investigators aim to identify point-of-care (POC) strategies that can improve TB case
      detection and clinical outcomes among patients with advanced HIV. The project includes a main
      study and two sub-studies.

      The main study is a multicenter stepped wedge cluster-randomized controlled trial of LF-LAM
      implementation among patients with advanced HIV with 8-weeks follow-up. LF-LAM will be added
      to standard care and implemented stepwise at three hospitals in Ghana. Education in national
      TB treatment guidelines in collaboration with the Tuberculosis Control programme in Ghana,
      and Clinical audit of clinical staff with feedback, will be used to assess and strengthen
      LF-LAM implementation. The primary outcome time to TB treatment, for which a sample size of
      690 participants will provide &gt;90% power to detect a minimum of 7 days reduction. Secondary
      outcomes are: TB related morbidity, TB case detection, time to TB diagnosis and overall early
      mortality at 8 weeks. The HIV-associated TB epidemiology including genotypic analyses of M.
      tuberculosis isolates obtained through the main study will be described. In sub study A,
      focused ultrasound of lungs, heart and abdomen will be performed in a sub cohort of 100
      participants. In sub study B, the investigators will establish a biobank and data warehouse
      for storage of blood, urine and sputum samples collected from participants that enter the
      study at Korle-Bu Teaching hospital.

      It is expected that LF-LAM will lead to earlier diagnosis and treatment of TB. Findings may
      further guide scaling-up of LF-LAM. The HIV-associated epidemic including genotypic
      properties and resistance properties which is important for improved management will be
      detailed. The investigators further expect to evaluate the potential of bedside ultrasound as
      a clinical tool in management of HIV/TB co-infected patients. The unique Ghanaian HIV-cohort
      and biobank may facilitate rapid evaluation of future prognostic biomarkers and new
      point-of-care TB diagnostic tests.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">August 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open label multi-center stepped wedge cluster-randomized controlled implementation trial of the use of urine-based LF-LAM in addition to routine sputum-based TB diagnostic tests to guide initiation of TB treatment among adult hospitalized patients with advanced HIV. The design offers a randomised method of evaluation of the intervention at cluster level. Applying the stepped wedge design ensures that all participating HIV/ART clinic attached wards will have received the intervention at the end of the study period, and provides the basis for the LF-LAM test to become an integrated part of TB health care services also after the project finishes. Clinic staff will be trained by the on how to use and interpret the LF-LAM test and in TB diagnostic guidelines as outlined by WHO. An Audit and feedback study will identify leaky steps in the TB diagnostic pathway and further strengthen the implementation and possible impact of the LF-LAM test.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to TB treatment initiation</measure>
    <time_frame>8 weeks follow up</time_frame>
    <description>Time to TB treatment initiation defined by time from TB diagnosis suspected to start of anti-tuberculous treatment provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TB related morbidity</measure>
    <time_frame>8 weeks follow up</time_frame>
    <description>The difference in the proportion of TB patients with reduced TB morbidity score at 8 weeks follow up using &quot;The Bandim tuberculosis score&quot; with grading 0-13, where a reduction in the score may be used as a measurement of clinical improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB case detection</measure>
    <time_frame>8 weeks follow up</time_frame>
    <description>Defined as proportion of patients with (i) microbiologically confirmed TB diagnosis and (ii) clinically confirmed TB diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to TB diagnosis</measure>
    <time_frame>8 weeks follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to all-cause mortality.</measure>
    <time_frame>8 weeks follow up</time_frame>
    <description>Mortality rates during follow up. Underpowered</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">690</enrollment>
  <condition>Extrapulmonary Tuberculosis</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture) + Intervention
Intervention: LF-LAM is made available at the study site for the clinical staff to use; Training of clinical staff in national TB guidelines and LF-LAM use together with staff from the National TB Programme in Ghana</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine TB diagnostic care (sputum smear microscopy, sputum Xpert MTB/Rif / sputum Xpert MTB/Rif Ultra, sputum culture)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LF-LAM</intervention_name>
    <description>Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lateral flow urine lipoarabinomannan assay</other_name>
    <other_name>Determine TM TB LAM Ag test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-positive

          -  18 years and above

          -  Able to give informed consent

          -  Admitted at the wards attached to the research site ART/HIV-clinic

          -  Eligible for LF-LAM testing (defined by WHO in the LF-LAM policy update 2019):
             CD4-cell-count ≤200 cells/μL (the last measured CD4-cell-count); or a WHO clinical
             stage 3 or 4 event at presentation for care; or seriously ill defined by WHO
             (respiratory rate &gt; 30/min, temperature &gt; 39°C, heart rate &gt; 120/min or unable to walk
             unaided); or a positive WHO TB symptom screening including one of the following
             symptoms: current cough, fever, weight loss, or night sweats

        Exclusion Criteria:

          -  Anti-tuberculous treatment including preventive treatment with Isoniazide within the
             last 60 days

          -  Earlier participation in the same study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Åhsberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Infectious Diseases, Odense University Hosp., Univ. of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isik Somuncu Johansen, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Infectious Diseases, Odense University Hosp., Univ. of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret Lartey, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>School of Medicine and Dentistry, University of Ghana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephanie Bjerrum, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Infectious Diseases, Odense University Hosp., Univ. of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Åse Bengaard Andersen, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Infectious Diseases, Odense University Hosp., Univ. of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernest Kenu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Epidemiology and Disease Control, Univ. of Ghana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Åhsberg, MD</last_name>
    <phone>+233 557663379</phone>
    <email>johanna.maria.aahsberg@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isik Somuncu Johansen, Prof</last_name>
    <phone>+45 65412652</phone>
    <email>isik.somuncu.johansen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korle Bu Teaching Hospital</name>
      <address>
        <city>Accra</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Ganu, MD</last_name>
      <phone>+233 208213108</phone>
      <email>vincentjganu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Peter Puplampu, MD</last_name>
      <phone>+233 244263582</phone>
      <email>pedpup@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Johanna Åhsberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Ganu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tema General Hospital</name>
      <address>
        <city>Tema</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akosua Osei-Manu, MD</last_name>
      <phone>+233 266690007</phone>
      <email>anitaaa679@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Augustine Kwashie, MD</last_name>
      <phone>+233 244281045</phone>
      <email>austinkwashie@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Margaret Lartey, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akosua Osei-Manu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lekma Hospital</name>
      <address>
        <city>Teshie</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Oliver-Commey, MD</last_name>
      <phone>+233 244264840</phone>
      <email>adjetna@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Margaret Lartey, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Oliver-Commey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ghana</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Johanna Maria Åhsberg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Point-of-care systems</keyword>
  <keyword>Tuberculosis/Diagnosis</keyword>
  <keyword>Biomarkers/Urin</keyword>
  <keyword>Lipopolysaccharides/urine</keyword>
  <keyword>Audit intervention</keyword>
  <keyword>Diagnostic tests/Routine</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Bedside</keyword>
  <keyword>Biobank</keyword>
  <keyword>Stepped wedge cluster randomised trial</keyword>
  <keyword>Multicenter study</keyword>
  <keyword>Audit and feedback</keyword>
  <keyword>Ghana</keyword>
  <keyword>Adult</keyword>
  <keyword>Hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

